Fawziah Marra1, James R Salzman, Mary H H Ensom. 1. Faculty of Pharmaceutical Sciences, University of British Columbia, and Pharmacy and Vaccine Services, British Columbia Centre for Disease Control, Vancouver, Canada. fawziah.marra@bccdc.ca
Abstract
OBJECTIVE: To review the currently available information on atovaquone-proguanil for treatment and prophylaxis of malaria. DATA SOURCES: A MEDLINE search was conducted from 1966 to February 2003 using key phrases Malarone, atovaquone, proguanil, and malaria. Further articles were identified from a manual search of the references of identified articles. STUDY SELECTION AND DATA EXTRACTION: English-language studies with animal and human data evaluating preclinical pharmacology, human studies on pharmacokinetics, and clinical trials were evaluated. Relevant data were extracted from identified articles. DATA SYNTHESIS: Atovaquone-proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. In these studies, treatment with atovaquone-proguanil led to a higher (87-100% vs. 72-88%) or equally effective (94-100% vs. 90-100%) cure rate than the comparator antimalarial agents. Atovaquone-proguanil has been evaluated for prophylaxis of malaria in 6 clinical trials. In the 4 placebo-controlled trials for semi-immune residents or nonimmune migrants, the prophylaxis success rates in the atovaquone-proguanil and placebo arms ranged from 98% to 100% and 48% to 82%, respectively. The prophylaxis with success rates were similar among the 2 arms when atovaquone-proguanil was compared with other antimalarial regimens in nonimmune travelers. Atovaquone-proguanil was well tolerated in these clinical trials. CONCLUSIONS: Atovaquone-proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria.
OBJECTIVE: To review the currently available information on atovaquone-proguanil for treatment and prophylaxis of malaria. DATA SOURCES: A MEDLINE search was conducted from 1966 to February 2003 using key phrases Malarone, atovaquone, proguanil, and malaria. Further articles were identified from a manual search of the references of identified articles. STUDY SELECTION AND DATA EXTRACTION: English-language studies with animal and human data evaluating preclinical pharmacology, human studies on pharmacokinetics, and clinical trials were evaluated. Relevant data were extracted from identified articles. DATA SYNTHESIS: Atovaquone-proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. In these studies, treatment with atovaquone-proguanil led to a higher (87-100% vs. 72-88%) or equally effective (94-100% vs. 90-100%) cure rate than the comparator antimalarial agents. Atovaquone-proguanil has been evaluated for prophylaxis of malaria in 6 clinical trials. In the 4 placebo-controlled trials for semi-immune residents or nonimmune migrants, the prophylaxis success rates in the atovaquone-proguanil and placebo arms ranged from 98% to 100% and 48% to 82%, respectively. The prophylaxis with success rates were similar among the 2 arms when atovaquone-proguanil was compared with other antimalarial regimens in nonimmune travelers. Atovaquone-proguanil was well tolerated in these clinical trials. CONCLUSIONS:Atovaquone-proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria.
Authors: Fiona Macintyre; Hanu Ramachandruni; Jeremy N Burrows; René Holm; Anna Thomas; Jörg J Möhrle; Stephan Duparc; Rob Hooft van Huijsduijnen; Brian Greenwood; Winston E Gutteridge; Timothy N C Wells; Wiweka Kaszubska Journal: Malar J Date: 2018-11-01 Impact factor: 2.979